ArticleJournal of clinical medicine2019

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.

Ruediger B Mueller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.